Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten O Nielsen

Showing results (51-60 of 212) with videos related to

Pageof 22
Sort By:
Oncotarget|April 28, 2016
Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assayAimée N Laporte, Jennifer X Ji, Limin Ma, et al.
The Lancet. Oncology|August 7, 2007
CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors' replyJay S Wunder, Torsten O Nielsen, Robert G Maki, et al.
Sarcoma|October 29, 2010
Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell TumorHongwei Cheng, Paul W Clarkson, Dongxia Gao, et al.
Journal of the National Cancer Institute|May 18, 2021
Response to Zhang and YangTorsten O Nielsen, Samuel C Y Leung, Lisa M McShane, et al.
NPJ Breast Cancer|March 11, 2025
Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancerMaj-Britt Jensen, Torsten O Nielsen, John Bartlett, et al.
The Journal of Molecular Diagnostics : JMD|December 12, 2022
Diagnosis of Fusion-Associated Sarcomas by Exon Expression Imbalance and Gene ExpressionAngela Goytain, Kenneth Tou En Chang, Jian Yuan Goh, et al.
Neoplasia (New York, N.Y.)|June 21, 2019
The FUS-DDIT3 Interactome in Myxoid LiposarcomaJamie S E Yu, Shane Colborne, Christopher S Hughes, et al.
Acta Oncologica (Stockholm, Sweden)|November 24, 2017
Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trialsMaj-Britt Jensen, Torsten O Nielsen, Ann S Knoop, et al.
Breast Cancer Research : BCR|September 7, 2014
Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltrationShuzhen Liu, William D Foulkes, Samuel Leung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Breast cancer subtypes and the risk of local and regional relapseK David Voduc, Maggie C U Cheang, Scott Tyldesley, et al.
Pageof 22

Showing results (51-60 of 212) with videos related to

Sort By:
Pageof 22
Oncotarget|April 28, 2016
Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assayAimée N Laporte, Jennifer X Ji, Limin Ma, et al.
The Lancet. Oncology|August 7, 2007
CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors' replyJay S Wunder, Torsten O Nielsen, Robert G Maki, et al.
Sarcoma|October 29, 2010
Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell TumorHongwei Cheng, Paul W Clarkson, Dongxia Gao, et al.
Journal of the National Cancer Institute|May 18, 2021
Response to Zhang and YangTorsten O Nielsen, Samuel C Y Leung, Lisa M McShane, et al.
NPJ Breast Cancer|March 11, 2025
Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancerMaj-Britt Jensen, Torsten O Nielsen, John Bartlett, et al.
The Journal of Molecular Diagnostics : JMD|December 12, 2022
Diagnosis of Fusion-Associated Sarcomas by Exon Expression Imbalance and Gene ExpressionAngela Goytain, Kenneth Tou En Chang, Jian Yuan Goh, et al.
Neoplasia (New York, N.Y.)|June 21, 2019
The FUS-DDIT3 Interactome in Myxoid LiposarcomaJamie S E Yu, Shane Colborne, Christopher S Hughes, et al.
Acta Oncologica (Stockholm, Sweden)|November 24, 2017
Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trialsMaj-Britt Jensen, Torsten O Nielsen, Ann S Knoop, et al.
Breast Cancer Research : BCR|September 7, 2014
Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltrationShuzhen Liu, William D Foulkes, Samuel Leung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Breast cancer subtypes and the risk of local and regional relapseK David Voduc, Maggie C U Cheang, Scott Tyldesley, et al.
Pageof 22